Lymphoma Action ensure that the patient voice is heard at HTAs, resulting in better access to the latest treatments.
Tafasitamab plus lenalidomide show promise for people with relapsed or refractory DLBCL who are not suitable for a stem cell transplant.
Selinexor shows early potential for people with relapsed or refractory DLBCL who have had at least two previous courses of treatment.
The American Society of Clinical Oncology (ASCO) held a virtual conference at the end of May.
Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.
Clinical trial results published.
A new blood test has been developed that could be used to screen for more than 50 types of cancer, including lymphoma.
Results of the LEGEND trial of a lenalidomide-based regimen in DLBCL have been published in the Annals of Haematology.
The FLYER study found that four cycles of R-CHOP was no less effective than six cycles in people with stage 1 or 2 high-grade B-cell lymphoma and no risk factors.
Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia